Company Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally.
The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, which is in Phase I clinical trial to treat non-small cell lung cancer.
It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
In addition, the company is developing RND1, a cell transplant program for an undisclosed indication through a gene editing collaboration, engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology.
Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme.
The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019.
Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
| Country | United States |
| Founded | 1990 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 77 |
| CEO | Brian Culley |
Contact Details
Address: 2173 Salk Avenue, Suite 200 Carlsbad, California 92008 United States | |
| Phone | 442 287 8990 |
| Website | lineagecell.com |
Stock Details
| Ticker Symbol | LCTX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000876343 |
| CUSIP Number | 53566P109 |
| ISIN Number | US53566P1093 |
| Employer ID | 94-3127919 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Rami Skaliter Ph.D. | Chief Executive Officer of Cell Cure Neurosciences |
| Brian M. Culley M.A., M.B.A. | Chief Executive Officer, President and Director |
| Jill Ann Howe | Chief Financial Officer and Principal Financial and Accounting Officer |
| George A. Samuel III, J.D. | General Counsel and Company Secretary |
| Ioana C. Hone | Director of Investor Relations |
| Dr. Charlotte Hubbert Ph.D. | Vice President of Corporate Development |
| Brandi L. Roberts CPA, M.B.A. | Consultant |
| Alexandra Hernandez | Senior Director of Finance and Controller |
| Dr. Harold D. Waitz | Vice President of Regulatory Affairs and Quality Control |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 17, 2025 | SCHEDULE 13G/A | Filing |
| Jul 2, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 11, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 9, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| May 1, 2025 | 8-K | Current Report |
| Apr 29, 2025 | ARS | Filing |
| Apr 29, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |